Zio MCT FDA Filing Pushed to 2027 as Q3 Miss Sends Shares to 52-Week Low
IRTC is trading near its 52-week low of $86.3 (3.4% above the low) on elevated volume (5.6× avg).
Summary
iRhythm pushed its Zio MCT FDA submission out of 2026 and into 2027, a delay CEO Quentin Blackford tied to prioritizing integration of the FDA-cleared MCT product acquired in the $287.5M VitalConnect deal that closed in early October. The Q3 print was also short: adjusted EPS of -$0.90 missed by $0.95 and revenue of $221.6M missed by $0.6M, with the GAAP loss inflated by a $49.8M litigation settlement charge disclosed in the 10-Q. The one offset is guidance — FY26 revenue was raised to $890M-$895M from $880M-$890M, above the $890.6M consensus midpoint. The stock fell to a new 52-week low near $86, extending a slide from a $192.47 high, so the market is treating the pipeline delay as the bigger issue than the modest guidance raise. Watch the 2027 Zio MCT filing timeline and whether Zio AT replacement plans slip with it.
At the time of this announcement, IRTC was trading at $89.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $86.30 to $192.47. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.